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Background. Two single-point mutations of the Plasmodium falciparum cytochrome b gene (Tyr268Asn and
Tyr268Ser) were recently reported in cases of atovaquone/proguanil (Malarone) treatment failure. However, little
is known about the prevalence of codon-268 mutations and their quantitative association with treatment failure.
Methods. We set out to assess the prevalence of codon-268 mutations in P. falciparum isolates imported into
Europe and to quantify their association with atovaquone/proguanil treatment failure. Isolates of P. falciparum collected
by the European Network on Imported Infectious Disease Surveillance between April 2000 and August 2003 were
analyzed for codon-268 mutations, by use of polymerase chain reaction–restriction fragment–length polymorphism.
Results. We successfully screened 504 samples for the presence of either Tyr268Ser or Tyr268Asn. One case of
Ser268 and no cases of Asn268 were detected. Therefore, we can be 95% confident that the prevalence of Ser268 in
the European patient pool does not exceed 0.96% and that Asn268 is less frequent than 0.77%. In 58 patients treated
with atovaquone/proguanil, Tyr268Ser was present in 1 of 5 patients with treatment failure but in 0 of 53 successfully
treated patients.
Conclusions. Tyr268Ser seems to be a sufficient, but not a necessary, cause for atovaquone/proguanil treatment
failure. The prevalence of both codon-268 mutations is currently unlikely to be 11% in the European patient pool.
Infected European travelers and immigrants carry a wide
variety of Plasmodium falciparum strains from all en-
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demic areas into the continent. Thus, if properly done,
data and parasite material from this population can be
used to monitor the development of drug resistance in
endemic areas, especially in sub-Saharan Africa [1].
A fixed combination of atovaquone and proguanil
(Malarone; GlaxoSmithKline) is a drug that has been
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recently introduced for the treatment and prophylaxis of mul-
tidrug-resistant P. falciparum malaria. Early evidence showed
that parasites may quickly develop resistance to atovaquone.
One study showed that, when treated with atovaquone alone,
33% of patients had recrudescence of parasitemia [2]. It has
been proposed that, because atovaquone inhibits electron trans-
port and collapses mitochondrial membrane potential at similar
concentrations [3], this might lead to the formation of oxygen
radicals, which could act as locally active mutagens [4].
When atovaquone is administered in combination with pro-
guanil, cure rates of 99%–100% are achieved [5–10]. It has
been shown that the biguanide itself, not the metabolic con-
version cycloguanil as an inhibitor of dihydrofolate reductase,
synergizes with atovaquone by specifically lowering the con-
centrations at which atovaquone is able to collapse the mito-
chondrial membrane electropotential [11]. As a result, the in-
clusion of proguanil leads to an enhancement of atovaquone’s
activity and reduces the chance of mutations arising in the
mtDNA of the malaria parasite [4].
There is evidence that atovaquone, on the basis of its struc-
tural similarity to ubiquinol, binds to the parasitic cytochrome
bc1 (cyt b) complex [12], and mutations in the cyt b gene of
the parasite mitochondrial genome have been described that
confer atovaquone resistance. Two mutations in Pneumocystis
carinii at the ubichinol-binding pocket (the Q0 domain) have
been shown to be associated with the failure of atovaquone
prophylaxis [13]. Atovaquone-resistant Plasmodium yoelii lines
have been derived by subtherapeutic treatment of infected mice.
Five mutations near the putative atovaquone-binding pocket
have been identified at codons 258–272 [14]. In a similar study,
3 mutations at the cyt b gene of atovaquone-resistant Plasmo-
dium berghei lines were found to be associated with resistance
to atovaquone. In that study, mutations at codon 133 or 144,
in addition to an amino acid change at codon 284, led to in-
creased resistance levels [15].
In studies with P. falciparum, atovaquone-resistant lines have
been derived in vitro by incubation at various concentrations
[16]. An initial mutation at codon 133 was found to confer a
low resistance level that could be increased by additional mu-
tations in the codon 272–280 domain. In vivo, a P. falciparum
isolate from a Thai patient with recrudescence after atovaquone
and pyrimethamine treatment showed a mutation at codon 268
(Tyr268Ser) of the cyt b gene [2, 16]. A different amino acid
change at the same codon (Tyr268Asn) was described in an
English patient traveling to Nigeria who had failed atovaquone/
proguanil therapy [17].
Protocols for the detection of relevant mutations have been
developed and evaluated with in vitro isolates plus a few sam-
ples from patients with documented in vivo resistance. The
results point convincingly toward correlations between the de-
tection of point mutations and phenotypic resistance, in par-
ticular for correlation to the codon-268 mutations and in vivo
resistance. The cyt b gene mutations Tyr268Asn and Tyr268Ser
have been linked to cases of atovaquone/proguanil treatment
failure [17–21]. To move molecular assays for point mutations
on resistance-related genes into the realm of applied tools for
surveillance, we investigated a series of P. falciparum isolates
that had been imported into Europe between April 2000 and
August 2003 for the prevalence of point mutations associated
with atovaquone/proguanil resistance.
SUBJECTS, MATERIALS, AND METHODS
Sampling. The study was established within the infrastructure
of the European Network on Imported Infectious Disease Sur-
veillance (TropNetEurop), which has been successfully provid-
ing surveillance data on imported malaria since 1999 [22]. The
network covers ∼12% of all imported cases of malaria in west-
ern and central Europe. Sentinel surveillance reporting is cur-
rently done by 46 participating clinical sites throughout 16
European countries by use of a standardized and computerized
reporting system. Although the organization of the network
does not guarantee a representative data collection for Europe,
most referral centers in Europe are represented. A total of 18
centers sent in malaria isolates with their case notifications.
During standard malaria testing by thick and thin blood film,
10 mL of full blood was dotted on Whatman 3MM chroma-
tography paper and air-dried at room temperature before the
initiation of treatment. DNA was prepared from the dried blood
spots, as described elsewhere [23].
Polymerase chain reaction–restriction fragment–length poly-
morphism (PCR-RFLP) for codon-268 mutations. The de-
tection of resistance-related point mutations on the cyt b gene
was done according to protocols established elsewhere. For de-
tection of the codon-268 mutations on cyt b, a PCR-RFLP
method was used. Details have been published elsewhere [18].
A nested PCR was designed that used CYTb1 and CYTb2 as
outer primers and 3 different pairs of nested primers to dis-
tinguish the 3 known polymorphisms at codon 268. For the
primary amplification reaction, a mix that contained 0.125
mmol/L each outer primer, 0.2 mmol/L dNTPs, 1.5 mmol/L
Mg2+, and 0.5 U Taq polymerase (Qbiogene) was initially heat-
ed at 94C for 5 min and then cycled at 94C for 50 s, 50C
for 50 s, and 70C for 1 min for 35 cycles, with a final extension
at 70C for 5 min. For the secondary amplification, 1 mL of
PCR product was added to the master mix that contained 0.5
mmol/L primers and dNTP, MgCl2, and Taq polymerase, as
described above. PCR conditions were 94C for 5 min, 30 cycles
of 95C for 30 s, 55C for 30 s, 72C for 30 s, and a final
extension at 72C for 5 min for the primer pairs CYTb3/CYTb5
and CYTb2/CYTb6. CYTb2/CYTb7 was annealed at 45C. The
products of the second round were confirmed by electropho-
resis in ethidium bromide–stained agarose gel.
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Table 1. Characteristics of the total study population.
Characteristic
Total study population
(n p 504)
Male/female/no data 244/114/146
Median age (range), years 36 (0–83)
European/non-European/no data 167/177/160
Region of infection
West Africa 273 (54.2)
Central Africa 85 (16.9)
East Africa 69 (13.7)
South Africa and Madagascar 31 (6.2)
Southeast Asia 18 (3.6)
Indian subcontinent 7 (1.4)
South and Central America 5 (1.0)
Other 2 (0.4)
No data 14 (2.8)
Malaria prophylaxis
None 260 (51.6)
Mefloquine 18 (3.6)
Chloroquine/proguanil 18 (3.6)
Chloroquine only 12 (2.4)
Proguanil only 1 (0.2)
Atovaquone/proguanil 1 (0.2)
Other 7 (1.4)
No data 187 (37.1)
NOTE. Data are no. (%) of subjects, unless otherwise noted.
For RFLP analysis, 5 mL of PCR product was mixed with 1
U of the appropriate enzyme and its specific buffer in a total
volume of 22 mL and incubated overnight at 37C. The result
was detected by electrophoresis in ethidium bromide–stained
agarose gel. The primer pair CYTb3/CYTb5, when used in com-
bination with the enzyme NsiI, cuts the wild type (wt) and the
Asn268 mutation but not the Ser268 mutation. The primer pair
CYTb2/CYTb6, used in combination with the enzyme AlwNI,
cuts the Ser268 mutation but not the wt and the Asn268 mu-
tation. The primer pair CYTb2/CYTb7, used in combination
with the enzyme SspI, cuts the wt and the Ser268 mutation but
not the Asn268 mutation.
The established P. falciparum laboratory clones K1 and FCR3,
as well as our own in vitro isolates that are resistant to ato-
vaquone/proguanil, were used as representative controls [18].
In cases where the PCR testing of samples did not reveal any
result (neither wt nor mutation), the testing was repeated at
least once. If the PCR result remained inconclusive, the testing
was defined as unsuccessful, and the sample was excluded from
further analysis.
Statistical analysis. Results of the PCR testing of the P.
falciparum isolates were individually matched with epidemio-
logical and clinical data from the TropNetEurop surveillance da-
tabase and were analyzed by use of the statistical software SAS
(release 8.01; SAS Institute). To be able to present statistically
ascertained estimates for mutation prevalence, even if no mu-
tations were observed, maximum mutation prevalences were
calculated that, given the study power, one could be 95% sure
they were not surpassed. This may be interpreted as a 1-sided
95% confidence interval (CI). To derive the estimate, the num-
ber of to-be-expected mutations that, under the assumption
that the estimate was true, would make it !5% likely to find
the observed number of mutations or fewer in the sample had
to be determined. Under the assumption of Poisson distribu-
tion of the mutation data, the probability could be derived
from the distribution, which was defined as the number of
expected cases. Dividing the determined number of expected
cases by sample size yielded the maximum mutation prevalence.
RESULTS
A total of 504 isolates of P. falciparum were screened for 2
different mutations on codon 268 of the parasite’s cyt b gene,
which had been previously associated with atovaquone/pro-
guanil treatment failure. Combining the results of the PCRs
with primer pairs CTYb3/CYTb5 and CYTb2/CYTb6, both of
which focus on the detection of the Ser268 mutation, a total
of 495 samples were successfully screened for this specific mu-
tation. With the PCR using primer pair CYTb2/CYTb7, which
focuses on the detection of the Asn268 mutation, 391 samples
were tested successfully.
Characteristics of the total study population. Table 1 sum-
marizes the characteristics of the 504 patients. The majority of
infections (54.2%) were acquired in West Africa, and most
patients did not receive any malaria prophylaxis (82.0% of cases
with available data). The ratio of non-Europeans (immigrants
or foreign visitors) to Europeans (either living in Europe or ex-
patriates) was 1.06:1.
Characteristics of the treatment failures. Treatment infor-
mation was available for 329 of 504 patients. Of these, 253 re-
ceived drugs other than atovaquone/proguanil, 18 received ato-
vaquone/proguanil in combination with other drugs, and 58
received atovaquone/proguanil monotherapy. In the latter group,
5 treatment failures were reported. Of these, 3 cases of malaria
had been acquired in West Africa, 1 in East Africa, and 1 in
Central Africa (table 2).
Patient A, a 30-year-old Gambian who is a resident of
Germany, was diagnosed with P. falciparum monoinfection (3%
parasitemia) in September 2001 after returning from Gambia.
He did not receive any malaria prophylaxis during the visit.
The patient was treated with atovaquone/proguanil for 3 days;
no parasites were detected in the thick blood film 8 days after
the initiation of therapy. Three weeks after therapy, the patient
had a parasitological recrudescence without any symptoms.
Patient B, a 28-year-old male German, was diagnosed with
malaria in February 2002 in Mali, 8 days before he returned.
He received chloroquine and proguanil as malaria prophylaxis.
Treatment was provided with atovaquone/proguanil in ade-
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Table 2. Subsample of 58 travelers treated for malaria with
atovaquone/proguanil after returning to Europe.
Characteristic
Atovaquone/proguanil treatment
Failure
(np 5)
Success
(np 53)
Total
(np 58)
Male/female/no data 4/1/0 43/10/0 47/11/0
Median age (range), years 34 (28–57) 36 (16–83) 35.5 (16–83)
European/non-European/no data 2/3/0 22/31/0 24/34/0
Region of infection
West Africa 3 (60) 30 (56.6) 33 (56.9)
Central Africa 1 (20) 4 (7.5) 5 (8.6)
East Africa 1 (20) 11 (20.8) 12 (20.7)
South Africa and Madagascar … 6 (11.3) 6 (10.3)
Southeast Asia … 2 (3.8) 2 (3.4)
Malaria prophylaxis
None 2 (40) 41 (77.4) 43 (74.1)
Mefloquine … 1 (1.9) 1 (1.7)
Chloroquine/proguanil 1 (20) 5 (9.4) 6 (10.3)
Chloroquine only 1 (20) 3 (5.7) 4 (6.9)
Other … 2 (3.8) 2 (3.4)
No data 1 (20) 1 (1.9) 2 (3.4)
Prevalence of codon-268
mutations 1 (20) 0 (0) 1 (1.7)
NOTE. Data are no. (%) of subjects, unless otherwise noted.
quate doses. Four weeks later, the patient developed a symp-
tomatic recrudescence with a density of 1.5% P. falciparum.
PCR-RFLP and sequencing revealed a mutation (Tyr268Ser) in
the parasite’s cyt b gene [18].
Patient C, a 33-year-old male German, was diagnosed with
P. falciparum malaria after returning from a holiday in Kenya
and Tanzania in February 2003. He did not receive any malaria
prophylaxis. The patient developed a febrile recrudescence 3
weeks after directly observed treatment with atovaquone/pro-
guanil in standard doses.
Patient D, a 56-year-old male Nigerian who is a resident
of Spain, was diagnosed with P. falciparum malaria after re-
turning from Nigeria in March 2003. The patient was treated
with atovaquone/proguanil and developed an early treatment
failure with no negativity in the thick blood film.
Patient E, a 38-year-old Congolese woman who is a res-
ident of Germany, was diagnosed with P. falciparum mono-
infection after returning from a trip to Kinshasa. She received
only chloroquine for prophylaxis. Parasites recrudesced 3 weeks
after a directly observed standard treatment course of ato-
vaquone/proguanil. High-performance liquid chromatography
(Shimatzu) on day 2 of treatment confirmed a drug concen-
tration of atovaquone above the required therapeutic plasma
concentration (17.2 mg/mL).
All patients were retreated successfully either with coartem-
ether (artemether and lumefantrine; patients B, C, and D), other
artemisinin-based combinations (patient E), or mefloquine (pa-
tient A). Except for patient B, PCR-RFLP revealed wt in codon
268 of all isolates. In 4 of 5 isolates, PCR results were additionally
confirmed by sequencing a 716-bp fragment of the cyt b gene
[24], and no other variants were found.
Prevalence of codon-268 mutations. In our study popula-
tion, 1 case of Tyr268Ser (of 495) and 0 cases of Tyr268Asn (of
391) were detected. The prevalence of Tyr268Ser in patients
treated in Europe for falciparum malaria between 2001 and 2003
can therefore be calculated with 95% confidence to be 0.01%–
1.12%. The maximum prevalence that will not be surpassed with
5% probability of error can be calculated as 0.96%. For Tyr-
268Asn, we can be 95% confident that the prevalence of this
mutation does not exceed 0.77% in the European patient pool.
Association of codon-268 mutations with treatment failure.
In the subsample of 58 patients treated with atovaquone/pro-
guanil, Tyr268Ser was present in 1 of 5 with treatment failure
but in 0 of 53 successfully treated patients (table 2), which
indicates that this mutation is not a necessary, but may be a
sufficient, cause of atovaquone/proguanil treatment failure. Its
presence was associated with a 14.3-times higher risk of atova-
quone/proguanil treatment failure (relative risk [RR], 14.3 [95%
CI, 5.5–36.7]).
Tyr268Asn was detected in none of the samples; however, in
6 of 58 samples, the testing for this specific mutation was not
successful, and the status therefore remained unknown. Ex-
cluding these 6 samples from the analysis revealed a 12.8-times
higher risk for the occurrence of atovaquone/proguanil treat-
ment failure in the presence of either of the 2 described codon-
268 mutations (RR, 12.75 [95% CI, 5.0–32.7]).
DISCUSSION
With growing international travel and the continued spread of
antimalarial drug resistance, the new fixed-dose combination of
atovaquone and proguanil was most warranted as an agent that
is not only highly effective for the prophylaxis and treatment of
multidrug-resistant P. falciparum malaria but is also well toler-
ated, especially when it is used for prophylaxis [25, 26]. However,
early after its introduction, it was predicted that the combination
of these 2 agents, which had already been in use for some time,
would be vulnerable to resistance in the near future [27]. This
is even more the case in drugs in which single- or double-point
mutations confer high levels of resistance.
An atovaquone/proguanil donation program in Kenya and
Uganda implemented in 1999 (and discontinued in 2001) [28]
gave rise to concerns that atovaquone/proguanil needs to be
protected, because new, safe, and affordable antimalarial drugs
are unlikely to be developed in the near future [29]. Protection
can be achieved by judicious use and by combining atovaquone/
proguanil with artemisinin derivates, as is practiced in Thailand
[30]. But the combination of atovaquone/proguanil with ar-
temisinin derivates will be largely unaffordable in the devel-
oping world.
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The present study was performed to screen imported isolates
of P. falciparum for mutations previously reported to be as-
sociated with in vivo atovaquone/proguanil resistance. In 504
samples, 495 were successfully tested for Tyr268Ser and 391 for
Tyr268Asn on codon 268 of the parasite’s cyt b gene. One of
these mutations (Tyr268Ser) was detected. The fact that 2 inde-
pendent PCRs were used to reveal the presence of the Tyr268-
Ser mutation, whereas only 1 focused on the Asn268 mutation,
explains the different success rates of the testing. Technical as-
pects of the PCR protocols might also be responsible for this
discrepancy. Given the size of our sample, it can be derived
with a 5% probability of error that the prevalence of Tyr268Ser
in the European patient pool is !0.96% and that the prevalence
of Tyr268Asn is !0.77%.
In our subsample, 5 (8.62%) of 58 patients had atovaquone/
proguanil treatment failure. Compared with a large study per-
formed in Thailand ( ), where failures occurred in 2.8%np 530
of patients treated with atovaquone/proguanil alone, this is an
unexpectedly high number [31]. Because the reporting within
our network is self-selected, it might be assumed that treatment
failures are more likely to be reported (and subsequently over-
represented) in our population. Therefore, this number must
be interpreted with caution. Poor compliance with the treat-
ment regimen can be excluded in all 5 cases. Impaired bio-
availability of the drug could serve as another explanation of
recrudescence. For atovaquone, concomitant food intake plays
an important role, because of a food-induced increase in drug
solubility and, hence, bioavailability [32]. The drug concentra-
tion of atovaquone has been measured (and was sufficient) in
only 1 of the patients (patient E). In this case, the P. falciparum
isolate did not carry any codon-268 mutation. According to
our data, Tyr268Ser seems to be a sufficient, but not a necessary,
cause for atovaquone/proguanil treatment failure—it was pres-
ent in only 1 of 5 patients in the atovaquone/proguanil failure
group but in none of the successfully treated patients. Because
Tyr268Asn was ruled out as a cause of the observed atovaquone/
proguanil failures, it might be assumed that other mechanisms
or other mutations on the cyt b gene might contribute to the
development of resistance, in addition to the previously de-
scribed codon-268 mutations. However, in 4 of 5 isolates, all
mutations previously described as involved in atovaquone re-
sistance in vivo and in vitro [16] were ruled out by sequencing
a 716-bp fragment of the cyt b gene [24].
It is important to stress that atovaquone/proguanil is a slow-
acting antimalarial compound. In the above-mentioned study
from Thailand, 36 (6.8%) of 530 patients in the atovaquone/
proguanil group still had a positive blood film on day 3, com-
pared with 2 (0.4%) of 533 artesunate-mefloquine recipients
[31]. Therefore, late parasite clearance might be misinterpreted
as early treatment failure. In our study population, 4 of 5 pa-
tients with treatment failure developed the recrudescence 3
weeks after atovaquone/proguanil therapy, with several negative
blood smears in between. Reinfection can be excluded in 4
cases, because therapy was initiated in a European country. The
other patient left the endemic area 8 days after the last dose
of atovaquone/proguanil was received. Considering the intra-
hepatic efficacy of atovaquone, it does not seem likely that the
patient was reinfected during that time.
CONCLUSION
This type of molecular surveillance has little effect on treatment
decisions for the individual travelers returning from regions
where falciparum malaria is endemic. The high failure rate of
atovaquone/proguanil in our population may be attributed to
overreporting. Nevertheless, careful treatment follow-ups are
recommended after therapy with all antimalarial drugs. Codon-
268 mutations located on the parasite’s cyt b gene seem to be
a sufficient, but not a necessary, cause for atovaquone/proguanil
treatment failure. Further studies are recommended to elucidate
the mechanisms of resistance development and drug failure.
When used within a large clinical network, screening for
molecular resistance markers in travelers with falciparum ma-
laria has an unsurpassed advantage. When efficient methods
and reliable molecular markers are available, data on their prev-
alence can be used as an early warning system for changes
occurring in endemic areas, thus providing additional infor-
mation that may be crucial for regional and international drug-
policy changes. With regard to the 2 codon-268 mutations,
Tyr268Ser and Tyr268Asn, which have previously been de-
scribed in patients with atovaquone/proguanil treatment fail-
ure, we can be 95% confident that the current prevalence in
the European patient pool is !0.96% and !0.77%, respectively.
To the best of our knowledge, this is the first large-scale study
on the prevalence of codon-268 mutations in a series of im-
ported P. falciparum isolates and is the first attempt to quantify
the association between the prevalence of these mutations and
atovaquone/proguanil treatment failure.
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